心通医疗-B（02160）今日盘中大跌5.41%，引发市场关注。这一跌幅与公司昨晚发布的2024年度业绩报告密切相关。
根据公告，心通医疗-B截至2024年12月31日止年度的收入为3.62亿元人民币，同比增长7.54%。尽管公司股东应占亏损同比大幅收窄89.51%至4944.6万元，每股基本亏损降至0.02元，但投资者似乎对这一业绩表现并不满意。
分析人士指出，虽然心通医疗-B在收入增长和亏损收窄方面取得了进展，但公司仍未能实现盈利。市场反应表明，投资者可能预期更好的业绩表现，或对公司持续亏损状况感到担忧。此外，公司TAVI产品海外收入的高速增长以及新产品AnchorMan®系列的商业化虽为收入增长做出贡献，但似乎未能完全打消市场的顾虑。在当前经济环境下，投资者对医疗科技公司的盈利能力和增长前景可能保持谨慎态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.